This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 2, 2012 4:30 PM ET
Martin McGlynn – President and CEO
Rodney Young – CFO and VP, Finance and Administration
Stephen Dunn – LifeTech Capital
Joe Pantginis – ROTH Capital Partners
Jason Kolbert – Maxim Securities
Luca Pancratov – ROTH Capital Partners
Welcome to the Q2 2012 StemCells, Inc. Earnings Conference Call. My name is Monica and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please note that this conference is being recorded.
I will now turn the call over to Martin McGlynn, President and Chief Executive Officer. You may begin.
Thank you, Monica. Welcome everybody and thank you for joining us today. On the call with me is Rodney Young, our Chief Financial Officer and he and I will deliver some prepared remarks. Rodney’s remarks will include a discussion on the financial results for the second quarter of this year, and then I will follow up with the discussion of some of the exciting activities going on at our company. And then as usual, we will open the lines for question-and-answer period.
So to begin, I’d like to hand over to Rodney Young, our Chief Financial Officer.
Thank you, Martin. Before we proceed, I would like to remind everyone again, that during the call today, we will be making some forward-looking statements, which reflect our current views and are based upon certain assumptions that may or may not ultimately prove valid. We assume no obligation to update these forward-looking statements anytime in the future and our actual results may differ materially from anything projected during today’s call due to risks and uncertainties to which we are subject. These risks and uncertainties are described in our public filings with the SEC and at the end of today’s press release and we encourage you to consult and review them.